Replacement Further Alliance Pharma plc Investment

RNS Number : 9134Q
Logistics Development Group PLC
23 February 2023
 

The "Further Alliance Pharma plc Investment" announcement published at 13:28 on 23 February 2023 (RNS Number 8890Q) erroneously stated the additional shares purchased as 18,686,042, being the resultant holding, instead of 5,841,042. All other details remain unchanged.

 

The full corrected announcement is provided below.

 

 

23 February 2023

 

Logistics Development Group plc

 

("LDG") or the "Company")

 

Further Alliance Pharma plc Investment

 

LDG is pleased to announce that, further to its announcement on 22 December 2022, it has purchased an additional 5,841,042 ordinary shares in Alliance Pharma plc ("Alliance") (LON:APH), at an average price of £0.5911 per ordinary share, for a total cash consideration of £3,452,782.

 

Following these purchases, LDG is interested in 18,686,042 Alliance ordinary shares, representing approximately 3.46% of Alliance's issued share capital.

 

Alliance is an international healthcare group founded in 1996 and headquartered in the United Kingdom. The company acquires, markets, and distributes consumer healthcare and prescription medicine products.

 

For the year ended 31 December 2021, Alliance reported an underlying pre-tax profit of £42.2 million. As at 30 June 2022, Alliance reported net assets of £296.9 million.

 

 

For enquiries:

 

Logistics Development Group plc

Via FTI Consulting

FTI Consulting

Nick Hasell

Alex Le May

Cally Billimore

+44 (0) 20 3727 1340

 

 

Strand Hanson Limited

(Financial and Nominated Adviser)

James Spinney

James Dance

Abigail Wennington

 

+44 (0) 20 7409 3494

Investec Bank plc

(Broker)

Gary Clarence

Harry Hargreaves

+44 (0) 20 7597 5970

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMZGZZRFKGFZM
UK 100

Latest directors dealings